FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981345> ?p ?o ?g. }

• W4379981345 endingPage "851" @default.
• W4379981345 startingPage "850" @default.
• W4379981345 abstract "Introduction: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) typically have poor outcomes following standard treatment. Loncastuximab tesirine (loncastuximab tesirine-lpyl; Lonca), an antibody-drug conjugate (ADC) comprising a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin, received accelerated (US) and conditional (EU) approval in R/R DLBCL after ≥2 lines of systemic therapy, based on data from the phase 2 LOTIS-2 trial (Caimi PF et al. Lancet Oncol. 2021;22[6]:790). Rituximab (R), an anti-CD20 monoclonal antibody, is part of standard immunotherapy for DLBCL, both as frontline therapy and in subsequent treatments. Preclinical evidence suggests the addition of R to anti-CD19 ADC therapy may result in prolonged tumor control (Ryan MC et al. Blood. 2017;130[18]:2018). LOTIS-5 aims to evaluate Lonca-R vs standard immunotherapy of R + gemcitabine + oxaliplatin (R-GemOx) in R/R DLBCL. Methods: This is a phase 3, randomized, open-label, 2-part, 2-arm, multicenter study of Lonca-R in patients with R/R DLBCL (NCT04384484). The study consists of a safety run-in phase with Lonca-R (part 1) and a randomized phase evaluating efficacy and safety of Lonca-R vs R-GemOx (part 2). Approximately 350 patients will be enrolled across both parts: part 1 has completed; part 2 will enroll approximately 330 patients (randomized 1:1) to achieve 262 events for the primary end point analysis of progression-free survival by independent central review. Secondary end points include overall survival, overall response rate (2014 Lugano classification), complete response rate, duration of response, frequency and severity of adverse events, change from baseline in laboratory values, concentration and pharmacokinetic parameters of Lonca (conjugated and total antibody and unconjugated PBD), and changes in patient-reported outcomes from baseline. The dosing regimen for Lonca-R is Lonca 150 μg/kg + rituximab 375 mg/m2 every 3 weeks (Q3W) for 2 cycles, then Lonca 75 μg/kg + rituximab 375 mg/m2 Q3W for up to 6 cycles. The dose regimen of R-GemOx is rituximab 375 mg/m2, gemcitabine 1000 mg/m2, and oxaliplatin 100 mg/m2 every 2 weeks for up to 8 cycles. Key eligibility criteria include age ≥18 years, pathologic diagnosis of DLBCL (including patients with DLBCL transformed from indolent lymphoma) or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, ≥1 line of prior systemic therapy, previous stem cell transplant >30 days (autologous) or >60 days (allogenic) prior to start of study drug or stem cell transplant ineligibility, and measurable disease. The randomized part of LOTIS-5 began in January 2022 and has an estimated primary completion date of June 2025; enrollment continues, with a total of 45 active sites across the US, Canada, Spain, France, Belgium, Italy, Switzerland, Czech Republic, Poland, and China. The research was funded by: ADC Therapeutics SA; medical writing: CiTRUS Health Group Keywords: molecular targeted therapies, combination therapies, ongoing trials Conflicts of interests pertinent to the abstract C. Carlo-Stella Consultant or advisory role ADC Therapeutics, Celgene/Bristol Myers Squibb, Karyopharm, Novartis, Sanofi, Roche, Merck Sharp & Dohme, Scenic Biotech Honoraria: Merck Sharp & Dohme, Janssen Oncology, AstraZeneca, Celgene, Incyte, Gilead Sciences, Roche M. Chung Stock ownership: The Oncology Institute A. Stathis Honoraria: Eli Lilly, Bayer, Roche, Novartis, Janssen Oncology, AstraZeneca Research funding: ADC Therapeutics , Pfizer, Roche, Novartis, Bayer, Eli Lilly, MEI Pharma, Cellestia, Debiopharm Group, Merck/MSD, Abbvie, Amgen, AstraZeneca, Incyte, Loxo, Philogen Y. Wang Employment or leadership position: ADC Therapeutics Stock ownership: Johnson and Johnson (Family Member) L. Wang Employment or leadership position: ADC Therapeutics M. Hamadani Consultant or advisory role AbGenomics, ADC Therapeutics, Celgene, Incyte, Janssen R&D, Omeros, Pharmacyclics, TeneoBio, Verastem Research funding: Astellas Pharma, Spectrum Pharmaceuticals, Takeda Other remuneration: Speakers’ bureau for AstraZeneca, BeiGene, Sanofi Genzyme" @default.
• W4379981345 created "2023-06-10" @default.
• W4379981345 creator A5003642180 @default.
• W4379981345 creator A5006164793 @default.
• W4379981345 creator A5011030256 @default.
• W4379981345 creator A5022008748 @default.
• W4379981345 creator A5034207286 @default.
• W4379981345 creator A5036322101 @default.
• W4379981345 creator A5040908287 @default.
• W4379981345 creator A5042459008 @default.
• W4379981345 creator A5048622832 @default.
• W4379981345 creator A5062322697 @default.
• W4379981345 creator A5083903993 @default.
• W4379981345 creator A5086720717 @default.
• W4379981345 date "2023-06-01" @default.
• W4379981345 modified "2023-10-17" @default.
• W4379981345 title "LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH <i>R</i>/<i>R</i> DLBCL" @default.
• W4379981345 doi "https://doi.org/10.1002/hon.3166_ot29" @default.
• W4379981345 hasPublicationYear "2023" @default.
• W4379981345 type Work @default.
• W4379981345 citedByCount "0" @default.
• W4379981345 crossrefType "journal-article" @default.
• W4379981345 hasAuthorship W4379981345A5003642180 @default.
• W4379981345 hasAuthorship W4379981345A5006164793 @default.
• W4379981345 hasAuthorship W4379981345A5011030256 @default.
• W4379981345 hasAuthorship W4379981345A5022008748 @default.
• W4379981345 hasAuthorship W4379981345A5034207286 @default.
• W4379981345 hasAuthorship W4379981345A5036322101 @default.
• W4379981345 hasAuthorship W4379981345A5040908287 @default.
• W4379981345 hasAuthorship W4379981345A5042459008 @default.
• W4379981345 hasAuthorship W4379981345A5048622832 @default.
• W4379981345 hasAuthorship W4379981345A5062322697 @default.
• W4379981345 hasAuthorship W4379981345A5083903993 @default.
• W4379981345 hasAuthorship W4379981345A5086720717 @default.
• W4379981345 hasBestOaLocation W43799813451 @default.
• W4379981345 hasConcept C121332964 @default.
• W4379981345 hasConcept C126322002 @default.
• W4379981345 hasConcept C142424586 @default.
• W4379981345 hasConcept C143998085 @default.
• W4379981345 hasConcept C168563851 @default.
• W4379981345 hasConcept C203092338 @default.
• W4379981345 hasConcept C2776694085 @default.
• W4379981345 hasConcept C2777063308 @default.
• W4379981345 hasConcept C2778559949 @default.
• W4379981345 hasConcept C2779338263 @default.
• W4379981345 hasConcept C2780653079 @default.
• W4379981345 hasConcept C31760486 @default.
• W4379981345 hasConcept C535046627 @default.
• W4379981345 hasConcept C71924100 @default.
• W4379981345 hasConcept C87355193 @default.
• W4379981345 hasConceptScore W4379981345C121332964 @default.
• W4379981345 hasConceptScore W4379981345C126322002 @default.
• W4379981345 hasConceptScore W4379981345C142424586 @default.
• W4379981345 hasConceptScore W4379981345C143998085 @default.
• W4379981345 hasConceptScore W4379981345C168563851 @default.
• W4379981345 hasConceptScore W4379981345C203092338 @default.
• W4379981345 hasConceptScore W4379981345C2776694085 @default.
• W4379981345 hasConceptScore W4379981345C2777063308 @default.
• W4379981345 hasConceptScore W4379981345C2778559949 @default.
• W4379981345 hasConceptScore W4379981345C2779338263 @default.
• W4379981345 hasConceptScore W4379981345C2780653079 @default.
• W4379981345 hasConceptScore W4379981345C31760486 @default.
• W4379981345 hasConceptScore W4379981345C535046627 @default.
• W4379981345 hasConceptScore W4379981345C71924100 @default.
• W4379981345 hasConceptScore W4379981345C87355193 @default.
• W4379981345 hasIssue "S2" @default.
• W4379981345 hasLocation W43799813451 @default.
• W4379981345 hasOpenAccess W4379981345 @default.
• W4379981345 hasPrimaryLocation W43799813451 @default.
• W4379981345 hasRelatedWork W2009096079 @default.
• W4379981345 hasRelatedWork W2058988606 @default.
• W4379981345 hasRelatedWork W2114699723 @default.
• W4379981345 hasRelatedWork W2320262955 @default.
• W4379981345 hasRelatedWork W2615513935 @default.
• W4379981345 hasRelatedWork W2771633521 @default.
• W4379981345 hasRelatedWork W2995532498 @default.
• W4379981345 hasRelatedWork W3125059937 @default.
• W4379981345 hasRelatedWork W3166594929 @default.
• W4379981345 hasRelatedWork W4284988128 @default.
• W4379981345 hasVolume "41" @default.
• W4379981345 isParatext "false" @default.
• W4379981345 isRetracted "false" @default.
• W4379981345 workType "article" @default.